I think the financing deal will be better received if it does not bring millions of additional shares along. Any good company, will be diluted by massive numbers of shares, more more for a penny such as Elite, the billion or billions pipeline notwithstanding. If anything, I would think that giving up a piece of the pie would be better received by investors because the pharma would be communicating confidence. A loan loaded to the gills with amenities for the lender would not do as well. Just my opinion; no links.
Market Data 
Markets 
AI
